Sarwer K, Lashari S, Rafaqat N, Maher , Raheem A, Rehman M
Egypt Heart J. 2024; 76(1):156.
PMID: 39645546
PMC: 11625047.
DOI: 10.1186/s43044-024-00587-y.
Guo X, Zhang J, Huang M, Song C, Nie C, Zheng X
ESC Heart Fail. 2024; 12(1):582-591.
PMID: 39417989
PMC: 11769645.
DOI: 10.1002/ehf2.15109.
Fragkiadakis K, Ktena N, Kalantidou A, Dermitzaki E, Anastasiou I, Papathanassiou S
Cells. 2024; 13(16.
PMID: 39195218
PMC: 11352956.
DOI: 10.3390/cells13161328.
Dong H, Yin C, Xiao D, Tang Y
Aging (Albany NY). 2024; 16(13):10860-10867.
PMID: 38972072
PMC: 11272120.
DOI: 10.18632/aging.205956.
Osterberg A, Ostman-Smith I, Green H, Gunnarsson C, Fredrikson M, Liuba P
J Cardiovasc Dev Dis. 2024; 11(4).
PMID: 38667723
PMC: 11050055.
DOI: 10.3390/jcdd11040105.
Clinical findings using echocardiography and plasma cardiac troponin I and pathological findings in dogs with hypertrophic cardiomyopathy: A retrospective study.
Ando T, Izawa T, Nishida H, Akiyoshi H
Open Vet J. 2023; 13(6):742-752.
PMID: 37545712
PMC: 10399649.
DOI: 10.5455/OVJ.2023.v13.i6.9.
Influence of cardiac biomarkers on predicting significant coronary artery disease in hypertrophic cardiomyopathy patients.
Guler A, Turkmen I, Atmaca S, Karakurt H, Kahraman S, Aydin S
Heart Vessels. 2023; 38(11):1329-1336.
PMID: 37414867
DOI: 10.1007/s00380-023-02287-0.
Circulating Biomarkers in Hypertrophic Cardiomyopathy.
Matthia E, Setteducato M, Elzeneini M, Vernace N, Salerno M, Kramer C
J Am Heart Assoc. 2022; 11(23):e027618.
PMID: 36382968
PMC: 9851432.
DOI: 10.1161/JAHA.122.027618.
Identification of key genes for hypertrophic cardiomyopathy using integrated network analysis of differential lncRNA and gene expression.
Cao J, Yuan L
Front Cardiovasc Med. 2022; 9:946229.
PMID: 35990977
PMC: 9386162.
DOI: 10.3389/fcvm.2022.946229.
Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis.
Jansen M, Algul S, Bosman L, Michels M, van der Velden J, de Boer R
ESC Heart Fail. 2022; 9(5):3418-3434.
PMID: 35842920
PMC: 9715795.
DOI: 10.1002/ehf2.14073.
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.
Edelberg J, Sehnert A, Mealiffe M, Del Rio C, McDowell R
Am J Cardiovasc Drugs. 2022; 22(5):497-510.
PMID: 35435607
PMC: 9467968.
DOI: 10.1007/s40256-022-00532-x.
Thromboembolism in Patients with Hypertrophic Cardiomyopathy.
Liu L, Liu Z, Chen X, He S
Int J Med Sci. 2021; 18(3):727-735.
PMID: 33437207
PMC: 7797548.
DOI: 10.7150/ijms.50167.
Pathophysiology, Clinical Characteristics of Diabetic Cardiomyopathy: Therapeutic Potential of Natural Polyphenols.
Atale N, Yadav D, Rani V, Jin J
Front Nutr. 2020; 7:564352.
PMID: 33344490
PMC: 7744342.
DOI: 10.3389/fnut.2020.564352.
Novel mutations of TCTN3/LTBP2 with cellular function changes in congenital heart disease associated with polydactyly.
Chen H, Yang Z, Hou H, Wang J, Wang X, Yang Q
J Cell Mol Med. 2020; 24(23):13751-13762.
PMID: 33098376
PMC: 7753982.
DOI: 10.1111/jcmm.15950.
Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques ().
Ueda Y, Yee J, Williams A, Roberts J, Christe K, Stern J
Comp Med. 2020; 70(5):348-357.
PMID: 32778203
PMC: 7574220.
DOI: 10.30802/AALAS-CM-19-000117.
Cardiac Biomarkers in Pediatric Cardiomyopathy: Study Design and Recruitment Results from the Pediatric Cardiomyopathy Registry.
Everitt M, Wilkinson J, Shi L, Towbin J, Colan S, Kantor P
Prog Pediatr Cardiol. 2019; 53:1-10.
PMID: 31745384
PMC: 6863618.
DOI: 10.1016/j.ppedcard.2019.02.004.
Modulation of ADAR mRNA expression in patients with congenital heart defects.
Altaf F, Vesely C, Sheikh A, Munir R, Shah S, Tariq A
PLoS One. 2019; 14(4):e0200968.
PMID: 31039163
PMC: 6490900.
DOI: 10.1371/journal.pone.0200968.
Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease.
Hernandez-Romero D, Sanchez-Quinones J, Vilchez J, Rivera-Caravaca J, de la Morena G, Lip G
Sci Rep. 2019; 9(1):6235.
PMID: 30996283
PMC: 6470309.
DOI: 10.1038/s41598-019-42727-4.
Imbalance in extracellular matrix degradation in urethral stricture.
Prihadi J, Sugandi S, Siregar N, Soejono G, Harahap A
Res Rep Urol. 2018; 10:227-232.
PMID: 30538969
PMC: 6251351.
DOI: 10.2147/RRU.S178904.
Risk stratification in hypertrophic cardiomyopathy.
Marrakchi S, Kammoun I, Bennour E, Laroussi L, Kachboura S
Herz. 2018; 45(1):50-64.
PMID: 29696341
DOI: 10.1007/s00059-018-4700-8.
